NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia.
Karle
J
J
Clemmesen
L
L
Hansen
L
L
Andersen
M
M
Andersen
J
J
Fensbo
C
C
Sloth-Nielsen
M
M
Skrumsager
B K
BK
Lublin
H
H
Gerlach
J
J
D000328:Adult; D001552:Benzazepines / Q000009:adverse effects* / Q000627:therapeutic use*; D001572:Benzofurans / Q000009:adverse effects* / Q000627:therapeutic use*; D018492:Dopamine Antagonists / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D015990:Placebo Effect; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors*; D012559:Schizophrenia / Q000188:drug therapy*; D016896:Treatment Outcome
D001552:Benzazepines; D001572:Benzofurans; D018492:Dopamine Antagonists; D017447:Receptors, Dopamine D1; C077122:5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol